Tenderwize
Zurück zur Suche

Open-House pharmaceutical supply agreement for Brinzolamid/Brimonidin

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Oct 31, 2027 · 431 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Brinzolamid/Brimonidin (amtlicher ATC-Code: S01EC24)

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

The notice says participation documents are obtained via the DTVP project room after access approval, and that some por...

The contracting authority states that demand is unknown and minimum purchase quantities are not guaranteed.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Conclusion of non-exclusive pharmaceutical rebate agreements under § 130a(8) SGB V for Brinzolamid/Brimonidin.
  • Open-House model: any interested company may join during the participation period if it meets and accepts the conditions.
Vollständige Zusammenfassung anzeigen

This is an Open-House pharmaceutical supply arrangement for the active substance Brinzolamid/Brimonidin (ATC S01EC24) with AOK PLUS. It is non-exclusive, open to all interested pharmaceutical companies that meet the stated participation conditions, with no individual negotiations and no guaranteed minimum purchase volume. Participation is handled electronically via DTVP, but submission is not via the bidder tool; the participation documents must be obtained from the project room after access approval. The notice is highly document-dependent, but the extracted procurement documents are not available beyond the XML notice text, so some submission details remain incomplete.

Risiken

The notice says participation documents are obtained via the DTVP project room after access approval, and that some por...

The contracting authority states that demand is unknown and minimum purchase quantities are not guaranteed.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.

Eligibility

  • The bidder must declare no mandatory or discretionary exclusion grounds using the provided self-declaration form.

Administrative

  • A declaration regarding Russia sanctions compliance is required using the specified form.

Auftraggeber

Ort

Erfurt, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE256878834

Tätigkeit

Health

Lose (1)

LOT-0001

Open-House pharmaceutical supply agreement for Brinzolamid/Brimonidin

Non-exclusive supply/framework-style Open-House agreement for pharmaceutical products containing Brinzolamid/Brimonidin (ATC S01EC24). Scope is the conclusion of rebate agreements with all eligible pharmaceutical companies. Place of performance is Dresden, Germany, with performance also linked to Saxony and Thuringia as stated in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Ort

Dresden, Germany

Dauer

Oct 2025 - Oct 2027

Kategorie

Pharmaceutical products

Frist

Deadline Oct 31, 2027

Vergabedetails

Veröffentlichungsdatum
24 Aug 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
551011-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3